J Korean Diabetes.  2021 Mar;22(1):21-25. 10.4093/jkd.2021.22.1.21.

Management of Hyperglycemia in Diabetic Kidney Disease

• Kim JM
• Kim SS

• KMID: 2526176
• DOI: http://doi.org/10.4093/jkd.2021.22.1.21

Abstract

Diabetes has reached epidemic proportions in Korea and worldwide, and is associated with increased risk for chronic kidney disease (CKD) and end-stage kidney disease (ESKD). Given the increasing prevalence of diabetes and its high morbidity and mortality, diabetic kidney disease (DKD) represents a serious concern in individual patients and a considerable socioeconomic burden. The kidneys contribute to glucose homeostasis through processes of gluconeogenesis, glucose filtration, glucose reabsorption, and glucose consumption. Decreased nephron mass and kidney dysfunction due to DKD progression lead to the complicated state that causes both hypoglycemia and hyperglycemia. Appropriate management tailored for DKD patients is required to improve their morbidity and mortality. This review focuses on special issues related to the management of DKD, including clinical kidney outcomes in DKD progression, glycemic control indices and targets for diabetes mellitus (DM) CKD, glucose management of advanced DM CKD or ESKD and tailored medications for DKD based on clinical evidence.

Keyword

Biomarkers; Diabetes mellitus; Diabetic nephropathies; Therapeutics

Reference

1. Eckardt KU., Coresh J., Devuyst O., Johnson RJ., Köttgen A., Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013. 382:158–69.

2. Mather A., Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011. (120):S1–6.

3. American Diabetes Association. 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019. 42(Suppl 1):S124–38.

4. Porrini E., Ruggenenti P., Mogensen CE., Barlovic DP., Praga M., Cruzado JM, et al. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2015. 3:382–91.

5. Jiang G., Luk AOY., Tam CHT., Xie F., Carstensen B., Lau ESH, et al. Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with type 2 diabetes. Kidney Int. 2019. 95:178–87.

6. Harjutsalo V., Groop PH. Epidemiology and risk factors for diabetic kidney disease. Adv Chronic Kidney Dis. 2014. 21:260–6.

7. Mulder S., Hamidi H., Kretzler M., Ju W. An integrative systems biology approach for precision medicine in diabetic kidney disease. Diabetes Obes Metab. 2018. 20(Suppl 3):6–13.

8. Looker HC., Mauer M., Saulnier PJ., Harder JL., Nair V., Boustany-Kari CM, et al. Changes in albuminuria but not GFR are associated with early changes in kidney structure in type 2 diabetes. J Am Soc Nephrol. 2019. 30:1049–59.

9. Waijer SW., Gansevoort RT., Heerspink HJL. Change in albuminuria as a surrogate endpoint. Curr Opin Nephrol Hypertens. 2019. 28:519–26.

10. Inker LA., Heerspink HJL., Tighiouart H., Levey AS., Coresh J., Gansevoort RT, et al. GFR slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019. 30:1735–45.

11. Abe M., Kalantar-Zadeh K. Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nat Rev Nephrol. 2015. 11:302–13.

12. Park J., Lertdumrongluk P., Molnar MZ., Kovesdy CP., Kalantar-Zadeh K. Glycemic control in diabetic dialysis patients and the burnt-out diabetes phenomenon. Curr Diab Rep. 2012. 12:432–9.

13. Reilly JB., Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Semin Dial. 2010. 23:163–8.

14. Little RR., Rohlfing CL., Tennill AL., Hanson SE., Connolly S., Higgins T, et al. Measurement of Hba1C in patients with chronic renal failure. Clin Chim Acta. 2013. 418:73–6.

15. Battelino T., Danne T., Bergenstal RM., Amiel SA., Beck R., Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019. 42:1593–603.

16. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC., Miller ME., Byington RP., Goff DC Jr., Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008. 358:2545–59.